Annovis Bio, Inc. (ANVS)

USD 4.71

(-7.83%)

Operating Expenses Summary of Annovis Bio, Inc.

Annovis Bio, Inc.'s latest annual operating expenses in 2023 was 45.03 Million USD , up 76.53% from previous year.
Annovis Bio, Inc.'s latest quarterly operating expenses in 2024 Q1 was 7.8 Million USD , down -25.21% from previous quarter.
Annovis Bio, Inc. reported a annual operating expenses of 25.51 Million USD in annual operating expenses 2022, up 75.93% from previous year.
Annovis Bio, Inc. reported a annual operating expenses of 14.5 Million USD in annual operating expenses 2021, up 164.47% from previous year.
Annovis Bio, Inc. reported a quarterly operating expenses of 7.8 Million USD for 2024 Q1, down -25.21% from previous quarter.
Annovis Bio, Inc. reported a quarterly operating expenses of 9.75 Million USD for 2023 Q2, down -2.11% from previous quarter.

Annual Operating Expenses Chart of Annovis Bio, Inc. (2023 - 2017)

Historical Annual Operating Expenses of Annovis Bio, Inc. (2023 - 2017)

Year	Operating Expenses	Operating Expenses Growth
2023	45.03 Million USD	76.53%
2022	25.51 Million USD	75.93%
2021	14.5 Million USD	164.47%
2020	5.48 Million USD	529.81%
2019	870.54 Thousand USD	21.94%
2018	713.93 Thousand USD	4.62%
2017	682.43 Thousand USD	0.0%

Year	Operating Expenses	Operating Expenses Growth
2024 Q2	7.76 Million USD	-0.6%
2024 Q1	7.8 Million USD	-25.21%
2023 Q2	9.75 Million USD	-2.11%
2023 Q3	14.86 Million USD	52.29%
2023 FY	45.03 Million USD	76.53%
2023 Q1	9.96 Million USD	214.61%
2023 Q4	10.44 Million USD	-29.74%
2022 Q3	7.67 Million USD	-12.33%
2022 Q2	8.75 Million USD	48.03%
2022 Q1	5.91 Million USD	-0.11%
2022 FY	25.51 Million USD	75.93%
2022 Q4	3.16 Million USD	-58.71%
2021 FY	14.5 Million USD	164.47%
2021 Q4	5.92 Million USD	107.45%
2021 Q3	2.85 Million USD	12.94%
2021 Q2	2.52 Million USD	-21.04%
2021 Q1	3.19 Million USD	87.69%
2020 Q4	1.7 Million USD	67.66%
2020 Q3	1.01 Million USD	-56.46%
2020 Q2	2.33 Million USD	448.56%
2020 FY	5.48 Million USD	529.81%
2020 Q1	425.72 Thousand USD	213.29%
2019 Q1	186.79 Thousand USD	11.15%
2019 Q4	135.88 Thousand USD	-43.8%
2019 Q3	241.79 Thousand USD	-21.0%
2019 FY	870.54 Thousand USD	21.94%
2019 Q2	306.07 Thousand USD	63.86%
2018 Q4	168.05 Thousand USD	22.0%
2018 FY	713.93 Thousand USD	4.62%
2018 Q3	137.74 Thousand USD	-36.86%
2018 Q2	218.16 Thousand USD	14.85%
2018 Q1	189.96 Thousand USD	0.0%
2017 FY	682.43 Thousand USD	0.0%

Peer Operating Expenses Comparison of Annovis Bio, Inc.

Name	Operating Expenses	Operating Expenses Difference
ADC Therapeutics SA	233.01 Million USD	80.673%
Alto Neuroscience, Inc.	37.8 Million USD	-19.112%
Biohaven Pharmaceutical Holding Company Ltd.	436.05 Million USD	89.672%
Ginkgo Bioworks Holdings, Inc.	1.1 Billion USD	95.937%
Nuvation Bio Inc.	99.82 Million USD	54.885%
Nuvation Bio Inc.	99.82 Million USD	54.885%
Arcus Biosciences, Inc.	457 Million USD	90.146%
Theriva Biologics, Inc.	21.43 Million USD	-110.14%
Zymeworks Inc.	196.76 Million USD	77.112%